Hot Mandates – Next Phase Newsletterhttps://blog.lifesciencenation.com
Life Science Nation Next Phase Newsletter
Mon, 19 Nov 2018 23:52:59 +0000 en
hourly
1 http://wordpress.com/https://lifesciencenationnewsletter.files.wordpress.com/2018/06/cropped-lsn-icon-s.png?w=32Hot Mandates – Next Phase Newsletterhttps://blog.lifesciencenation.com
3232Hot Investor Mandate: Life Sciences Investment Firm with Over $1B+ AUM Invests in Therapeutics, Devices, Diagnostics, Digital Health, and Drug Discovery & Research Toolshttps://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-life-sciences-investment-firm-with-over-1b-aum-invests-in-therapeutics-devices-diagnostics-digital-health-and-drug-discovery-research-tools/
https://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-life-sciences-investment-firm-with-over-1b-aum-invests-in-therapeutics-devices-diagnostics-digital-health-and-drug-discovery-research-tools/#respondThu, 15 Nov 2018 16:03:17 +0000http://blog.lifesciencenation.com/?p=12656A life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, is actively involved in innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences. These working relationships help give them a global footprint and vastly expand the firm’s deal flow.

The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. Bay City Capital funds have invested in a total of 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness.

The firm seeks to invest its capital in life sciences companies where their operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of their portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with their management teams to establish themselves as true partners in business building.

The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for their investments, and has established them as a preferred partner in the industry.

]]>https://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-life-sciences-investment-firm-with-over-1b-aum-invests-in-therapeutics-devices-diagnostics-digital-health-and-drug-discovery-research-tools/feed/0lsnewsletterHot Investor Mandate: Canada-Headquartered VC Firm Invests Up to $12M Over Life of Investment, with Strongest Interests in Therapeutics and Device Companieshttps://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-canada-headquartered-vc-firm-invests-up-to-12m-over-life-of-investment-with-strongest-interests-in-therapeutics-and-device-companies/
https://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-canada-headquartered-vc-firm-invests-up-to-12m-over-life-of-investment-with-strongest-interests-in-therapeutics-and-device-companies/#respondThu, 15 Nov 2018 16:02:18 +0000http://blog.lifesciencenation.com/?p=12657A life sciences Venture Capital firm based in Toronto with other offices throughout USA and Canada manages over $350M and is currently investing from a recently closed new fund. The firm typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in therapeutics and medical devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

]]>https://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-canada-headquartered-vc-firm-invests-up-to-12m-over-life-of-investment-with-strongest-interests-in-therapeutics-and-device-companies/feed/0lsnewsletterHot Investor Mandate: VC Firm Invests Up to $7M in Early-Stage Medical Devices & Diagnostics in Markets of Unmet Medical Need, Ideally of at Least $10Bhttps://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-vc-firm-invests-up-to-7m-in-early-stage-medical-devices-diagnostics-in-markets-of-unmet-medical-need-ideally-of-at-least-10b/
https://blog.lifesciencenation.com/2018/11/15/hot-investor-mandate-vc-firm-invests-up-to-7m-in-early-stage-medical-devices-diagnostics-in-markets-of-unmet-medical-need-ideally-of-at-least-10b/#respondThu, 15 Nov 2018 16:01:19 +0000http://blog.lifesciencenation.com/?p=12658An early-stage venture capital firm based in the bay area is currently making Seed and Series A investments into companies ranging from $500K to $7 million, depending on the stage and financial requirements of the company – with up to $15 million over the company’s lifetime. The firm has a preference for companies based in Silicon Valley, but will consider opportunities globally.

The firm is sector agnostic having its main screening criteria be that the company is operating in a white space (meaning little or no competition) and having potential market sizes of at least $10 billion from a bottoms-up view. That being said, companies in the life science space that the firm is most interested in include medical technology, devices, and diagnostics for massive unmet markets such as diabetes, hypertension, and obesity. Additionally, the firm is interested in lab and provider service companies, although the firm is very sensitive to market size (need to meet the aforementioned market size). Areas where the firm has been involved previously include a genomic cardiovascular diagnostic, bioinformatics, lab services and other diagnostics companies.

The firm looks to be the first institutional investor in companies and acts as a lead or co-lead investor. The firm looks to take an active board seat into companies and assist with many aspects of the company’s development. The firm considers experienced management teams and a history of success as a strong plus, but is comfortable in working with first-time entrepreneurs.